Clinical Trials
77 trialsA Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
Providence Health & Services
Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response
University Health Network, Toronto
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
MAGE-A10á¶â·âčâ¶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
Adaptimmune
AYAConnect
UNC Lineberger Comprehensive Cancer Center
EARN
Washington University School of Medicine
GLIMMER-01
Palleon Pharmaceuticals, Inc.
EDHITO
Institut Cancerologie de l'Ouest
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
MacroGenics
DELFI-L101
Delfi Diagnostics Inc.
Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer
University of Colorado, Denver
Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
Thomas Jefferson University
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Genomic Testing and Resulting Medical Decisions
Arbeitsgemeinschaft medikamentoese Tumortherapie
PREFER
Labcorp Corporation of America Holdings, Inc
MOM
Inova Health Care Services
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
Cedars-Sinai Medical Center
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
BioAtla, Inc.
ROOT
Taproot Health
DUET-3
Xencor, Inc.
Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients
Cedars-Sinai Medical Center
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
AcSĂ©
UNICANCER
Topical Anaesthesia in Cutaneous Head and Neck Surgery
University Hospital Waterford
CHEERS
University Hospital, Ghent
Study of the CD40 Agonistic Monoclonal Antibody APX005M
Apexigen America, Inc.
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
Eastern Cooperative Oncology Group
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
G-DEFINER
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
A Study of PRT1419 in Patients With Advanced Solid Tumors
Prelude Therapeutics
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
GASVERT
Institut de Cancérologie de Lorraine
DUET-2
Xencor, Inc.
Peroperative Assessment of Malignancies of the Head and Neck Using High-resolution 18F-FDG-PET/CT
University Hospital, Ghent
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
Ludwig Institute for Cancer Research
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
Roswell Park Cancer Institute
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
AbbVie
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
Incyte Corporation
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
Safety Study of MGA271 in Refractory Cancer
MacroGenics
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Fate Therapeutics
Investigator Initiated Phase 1 Study of TBI-1201
Mie University
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
University of California, San Francisco
Poly-ICLC
Oncovir, Inc.
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
University of Wisconsin, Madison